Nrx pharmaceuticals and nephron pharmaceuticals announce joint agreement to develop intravenous ketamine to treat suicidal depression

No current fda-approved formulation of ketamine for treatment of depression and suicidality partners are developing a proprietary, tamper and diversion-resistant formulation and packaging finished drug with two-year shelf stability targeted for november 2024, pending fda approval partners aim to submit new drug application by march 1, 2024 radnor, pa. and west columbia, s.c.
NRXP Ratings Summary
NRXP Quant Ranking